CA
Capital Advantage Portfolio holdings
AUM
$834M
Turnover
14.46%
1-Year Est. Return
15.6%
This Fund
S&P 500
This Quarter
Est. Return
-1.77%
1 Year Est. Return
+15.6%
3 Year Est. Return
+49.19%
5 Year Est. Return
+46.21%
10 Year Est. Return
–
AUM
$192M
AUM Growth
+$10.6M
(+5.9%)
Cap. Flow
+$14.2M
Cap. Flow
% of AUM
7.4%
Top 10 Holdings %
Top 10 Hldgs %
79.37%
Holding
57
New
1
Increased
26
Reduced
11
Closed
1
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.6
years
Top Buys
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$1.06M |
| 2 |
Meta Platforms (Facebook)
META
|
+$506K |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$462K |
| 4 |
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
|
+$211K |
| 5 |
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
|
+$179K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 87.01% |
| 2 | Technology | 2.67% |
| 3 | Energy | 2.08% |
| 4 | Industrials | 1.95% |
| 5 | Communication Services | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RDS.A
51
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $219K | 0.11% |
3,083
| – | – |
2014 Q2
1 quarter
|
|
52
Stryker
SYK
$108B
| $218K | 0.11% |
2,705
| – | – |
2013 Q4
3 quarters
|
|
53
SLB Ltd
SLB
$72B
| $205K | 0.11% |
2,019
| – | – |
2014 Q2
1 quarter
|
|
54
Bristol-Myers Squibb
BMY
$121B
| $203K | 0.11% |
+3,965
| New | +$198K |
2014 Q3
0 quarters
|
|
55
Sprott Physical Gold
PHYS
$14.7B
| $107K | 0.06% |
10,768
| – | – |
2013 Q4
3 quarters
|
|
|
56
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.51B
| – | – |
-3,517
| Closed | -$211K | – |
|
Similar funds
AWA
GWS
BEC
HA
ACGDR
NCM
SIG
AFA
Capital Advantage's Q3 2014 Portfolio in Review
As of Q3 2014, Capital Advantage held 57 positions worth $192M, up 5.9% from $181M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Capital Advantage deployed $14.2M of net new capital in Q3 2014, opening 1 new position and adding to 26 existing holdings. Its largest new stake was Bristol-Myers Squibb: 3,965 shares worth $203K.
By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, up from 87% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Vanguard Short-Term Corporate Bond ETF, an estimated $1.06M trimmed.
- Capital Advantage's largest Q3 2014 buy was Bristol-Myers Squibb: 3,965 shares worth $203K.
- Capital Advantage added most to Invesco BulletShares 2018 Corporate Bond ETF in Q3 2014, an estimated $3.12M increase.
- Capital Advantage's biggest Q3 2014 reduction was Vanguard Short-Term Corporate Bond ETF, cutting an estimated $1.06M.
- Capital Advantage fully exited iShares MSCI Emerging Markets Min Vol Factor ETF in Q3 2014, selling an estimated $211K.
- Capital Advantage's ten largest holdings make up 79% of its $192M portfolio in Q3 2014.
- Capital Advantage opened 1 new position and closed 1 in Q3 2014.
- Capital Advantage's portfolio value rose 5.9% quarter-over-quarter to $192M.
Based on Capital Advantage's 13F filing for Q3 2014, filed 22 Jun 2016.